Medtronic PLC $MDT Shares Sold by Perkins Coie Trust Co

Perkins Coie Trust Co lessened its holdings in shares of Medtronic PLC (NYSE:MDT) by 98.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 639 shares of the medical technology company’s stock after selling 38,106 shares during the quarter. Perkins Coie Trust Co’s holdings in Medtronic were worth $50,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in MDT. Vanguard Group Inc. increased its stake in shares of Medtronic by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 128,961,343 shares of the medical technology company’s stock valued at $12,388,027,000 after acquiring an additional 1,888,381 shares during the last quarter. State Street Corp boosted its position in shares of Medtronic by 2.0% in the fourth quarter. State Street Corp now owns 61,660,158 shares of the medical technology company’s stock worth $5,966,780,000 after acquiring an additional 1,199,621 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Medtronic by 2.7% in the fourth quarter. JPMorgan Chase & Co. now owns 53,616,694 shares of the medical technology company’s stock worth $5,150,420,000 after acquiring an additional 1,419,730 shares during the last quarter. Capital Research Global Investors grew its holdings in Medtronic by 12.6% in the fourth quarter. Capital Research Global Investors now owns 34,573,163 shares of the medical technology company’s stock valued at $3,321,101,000 after purchasing an additional 3,880,174 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Medtronic by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 27,879,481 shares of the medical technology company’s stock valued at $2,665,832,000 after purchasing an additional 231,919 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Price Performance

Shares of MDT stock opened at $89.31 on Tuesday. The firm has a fifty day simple moving average of $82.25 and a 200-day simple moving average of $86.55. The company has a market capitalization of $114.32 billion, a PE ratio of 23.94, a price-to-earnings-growth ratio of 2.34 and a beta of 0.55. Medtronic PLC has a twelve month low of $73.31 and a twelve month high of $106.33. The company has a current ratio of 2.13, a quick ratio of 1.62 and a debt-to-equity ratio of 0.52.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.01. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. The firm had revenue of $9.81 billion for the quarter, compared to the consensus estimate of $9.62 billion. During the same quarter in the previous year, the firm posted $1.62 EPS. The firm’s quarterly revenue was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Equities research analysts anticipate that Medtronic PLC will post 5.94 earnings per share for the current fiscal year.

Medtronic Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, July 17th. Investors of record on Friday, June 26th were paid a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 3.2%. This is a positive change from Medtronic’s previous quarterly dividend of $0.71. The ex-dividend date was Friday, June 26th. Medtronic’s payout ratio is presently 77.21%.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: UBS upgraded Medtronic to Buy from Neutral, describing a “turnaround” underway at the company. The upgrade suggests improving execution and renewed confidence in Medtronic’s ability to return to sustainable growth. Is Medtronic Becoming a Turnaround Story?
• Positive Sentiment: Medtronic is being promoted as an undervalued dividend-growth company, which may attract income-focused investors if the market begins to recognize potential for operational improvement and valuation expansion. Medtronic: Buy This Undervalued Dividend Aristocrat
• Positive Sentiment: Medtronic’s collaboration with Orchestra BioMed is progressing: the BACKBEAT pivotal trial remains on track to reach its enrollment target by the end of the third quarter of 2026, with primary data expected in the second quarter of 2027. Successful results could support future device-related growth. Orchestra BioMed Reports Second Quarter 2026 Results
• Neutral Sentiment: Recent coverage highlights Medtronic’s appeal relative to Johnson & Johnson and Abbott, but portrays the company more as a turnaround and valuation opportunity than a consistent high-growth story. Investors may continue to favor peers with stronger near-term organic growth. Johnson & Johnson vs. Medtronic Abbott vs. Medtronic

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $101.00 price target on shares of Medtronic in a research note on Wednesday, June 17th. Leerink Partners lowered their price objective on shares of Medtronic from $117.00 to $104.00 and set an “outperform” rating for the company in a research note on Thursday, June 4th. Wells Fargo & Company cut their target price on Medtronic from $114.00 to $102.00 and set an “overweight” rating on the stock in a research report on Thursday, June 4th. Rothschild & Co Redburn reduced their target price on Medtronic from $111.00 to $106.00 and set a “buy” rating on the stock in a report on Friday, June 5th. Finally, Truist Financial lowered their price target on Medtronic from $95.00 to $86.00 and set a “hold” rating for the company in a research report on Thursday, June 4th. Eighteen equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Medtronic presently has an average rating of “Moderate Buy” and a consensus target price of $98.83.

Insider Buying and Selling

In related news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $80.44, for a total value of $336,963.16. Following the completion of the transaction, the executive vice president owned 37,227 shares of the company’s stock, valued at approximately $2,994,539.88. This represents a 10.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.26% of the company’s stock.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).